Clinical trial
Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL
NCT00344786 · Biogen, Industry · Terminated
Key facts
| NCT number | NCT00344786 |
|---|---|
| Title | Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL |
| Official title | A Phase 1, Dose-Escalation Study of CNF2024 Administered Orally to Patients With B Cell Chronic Lymphocytic Leukemia (CLL) |
| Lead sponsor | Biogen, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | B-Cell Chronic Lymphocytic Leukemia |
| Intervention type | Drug |
| Interventions | CNF2024 (BIIB021) |
| Enrollment | 15 |
| Start date | Feb 1, 2006 |
| Primary completion | Jul 1, 2008 |
| Completion | Sep 1, 2008 |
| First posted | Jun 27, 2006 |
| Last update posted | Jun 5, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: